Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB)

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: KEVIN  URDAHL
Organization: SEATTLE CHILDREN'S HOSPITAL
Fiscal Year: 2024
Award: $5,443,065
Funding agency: National Institute of Allergy and Infectious Diseases

The goal of this program is to establish an integrated multi-disciplinary team of highly collaborative investigators that will plan and conduct iterative, in-depth immunologic analyses of tissue-specific and systemic responses in small animals, non-human primates (NHPs), and humans to identify the key immune responses needed for protection against Mtb and to identify immunologic targets that can be used to improve TB vaccine strategies. This study will assess whether co-infection with SARS-CoV2 has a significant impact on innate immunity in study participants spanning the Mycobacterium tuberculosis (Mtb) infection spectrum.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Animals><Body Tissues><COVID-19 virus><COVID19 virus><CoV-2><CoV2><Goals><Human><Immune><Immune Targeting><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Innate Immunity><Investigators><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><MTB vaccine><Modern Man><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Participant><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><TB infection><TB vaccine><Tissues><Tuberculosis><Tuberculosis Vaccines><Vaccine for TB><Vaccine for Tuberculosis><Wuhan coronavirus><anti-TB vaccine><co-infection><coinfection><coronavirus disease 2019 virus><coronavirus disease-19 virus><develop a vaccine><develop vaccines><development of a vaccine><disseminated TB><disseminated tuberculosis><hCoV19><host response><immune system response><immunoresponse><improved><infection due to Mycobacterium tuberculosis><mtb><multidisciplinary><nCoV2><non-human primate><nonhuman primate><programs><response><tuberculosis infection><tuberculous spondyloarthropathy><vaccine against M. tuberculosis><vaccine against Mtb><vaccine against Mycobacterium tuberculosis><vaccine against TB><vaccine against tuberculosis><vaccine candidates against tuberculosis><vaccine development><vaccine strategy>